DV
Publicaties op Oncologisch.com
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and ...
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
Daratumumab-bortezomib-lenalidomide-dexamethason bij myeloom: PERSEUS fase III